scholarly journals 137: End-of-life care in hematology and stem cell transplant patients and evaluation of a hematology-quality of dying assessment (H-QODA)

2007 ◽  
Vol 13 (2) ◽  
pp. 52
Author(s):  
P. Rowlings ◽  
H. Zhang ◽  
Y. Rohr
Keyword(s):  
Stem Cell ◽  
End Of Life ◽  
End Of Life Care ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Life Care ◽  
Quality Of Dying ◽  
Transplant Patients

scholarly journals End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center

2018 ◽  
Vol 54 (5) ◽  
pp. 700-706 ◽  
Author(s):  
Richard J. Lin ◽  
Theresa A. Elko ◽  
Miguel-Angel Perales ◽  
Koshy Alexander ◽  
Ann A. Jakubowski ◽  
...  
Keyword(s):  
Stem Cell ◽  
End Of Life ◽  
End Of Life Care ◽  
Stem Cell Transplant ◽  
Cancer Center ◽  
Cell Transplant ◽  
Life Care ◽  
Allogeneic Stem Cell Transplant

scholarly journals Validation of the Chinese version of the Care Evaluation Scale for measuring the quality of structure and process of end-of-life care from the perspective of bereaved family

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Juanjuan Zhao ◽  
Liming You ◽  
Hongmei Tao ◽  
Frances Kam Yuet Wong
Keyword(s):  
End Of Life ◽  
End Of Life Care ◽  
Mainland China ◽  
Chinese Version ◽  
Life Care ◽  
Quality Of Dying ◽  
Bereaved Family ◽  
Quality Of Structure ◽  
Care Evaluation

Abstract Background Assessing the quality of structure and process of end-of-life care can help improve outcomes. There was currently no valid tool for this purpose in Mainland China. The aim of this study is to validate the Chinese version of the Care Evaluation Scale (CES). Methods From January to December 2017, a cross-sectional online survey was conducted among bereaved family members of cancer patients from 10 medical institutes. The reliability of the CES was assessed with Cronbach’s α, and structural validity was evaluated by confirmatory factor analysis. Concurrent validity was tested by examining the correlation between the CES total score and overall satisfaction with end-of-life care, quality of dying and death, and quality of life. Results A total of 305 valid responses were analyzed. The average CES score was 70.7 ± 16.4, and the Cronbach’s α of the CES was 0.967 (range: 0.802–0.927 for the 10 domains). The fit indices for the 10-factor model of CES were good(root-mean-square error of approximation, 0.047; comparative fit index, 0.952; Tucker–Lewis index, 0.946; standardized root mean square residual, 0.053). The CES total score was highly correlated with overall satisfaction with medical care (r = 0.775, P < 0.01), and moderately correlated with patients’ quality of life (r = 0.579, P < 0.01) and quality of dying and death (r = 0.570, P < 0.01). In addition, few associations between CES total score and demographic characteristics, except for the family members’ age. Conclusions The Chinese version of the CES is a reliable and valid tool to evaluate the quality of structure and process of end-of-life care for patients with cancer from the perspective of bereaved family in Mainland China.

A randomized control trial of stress management for caregivers of stem cell transplant patients: Effect on patient quality of life and caregiver distress

2019 ◽  
Vol 28 (8) ◽  
pp. 1614-1623 ◽  
Author(s):  
Mark L. Laudenslager ◽  
Teresa L. Simoneau ◽  
Susan K. Mikulich‐Gilbertson ◽  
Crystal Natvig ◽  
Benjamin W. Brewer ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Stem Cell ◽  
Stress Management ◽  
Randomized Control Trial ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Caregiver Distress ◽  
Transplant Patients ◽  
Randomized Control

scholarly journals Quality of dying and quality of end-of-life care of nursing home residents in six countries: An epidemiological study

2018 ◽  
Vol 32 (10) ◽  
pp. 1584-1595 ◽  
Author(s):  
Lara Pivodic ◽  
Tinne Smets ◽  
Nele Van den Noortgate ◽  
Bregje D Onwuteaka-Philipsen ◽  
Yvonne Engels ◽  
...  
Keyword(s):  
Nursing Home ◽  
End Of Life ◽  
Epidemiological Study ◽  
End Of Life Care ◽  
Nursing Home Residents ◽  
Life Care ◽  
Quality Of Dying

Patients' perspectives on participation in clinical trials and palliative end-of-life care for management of advanced cancers in Nigeria.

2017 ◽  
Vol 35 (31_suppl) ◽  
pp. 78-78
Author(s):  
Jideuma Ikenna Egwim ◽  
Smita Palejwala
Keyword(s):  
Clinical Trials ◽  
End Of Life ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
End Of Life Care ◽  
Life Care ◽  
Advanced Cancer Patients ◽  
Incurable Cancer ◽  
Quality Of Dying

78 Background: Advanced cancers remain a major cause of mortality in Nigeria. Participation in clinical trials (PCTs) and palliative end-of-life care (PEOLC) are two approaches to incurable cancer management in the developed nations but these have been less adopted in Nigeria. This study set out to determine patients’ preferred approach between PCTs and PEOLC for management of advanced cancers in Nigeria. Methods: A survey of 120 advanced cancer patients was conducted using a questionnaire with 5-point Likert scale, variables of interest included demographic information, knowledge and perception about PCTs and PEOLC. Results: Majority of the patients (84%) agree PCTs is an option in management of incurable cancer but just about half accept it is beneficial and will improve their QOL, as against PEOLC, where all the patients considered it an option and deem it beneficial; with 99% and 98% respectively agreeing it will enhance their QOL and that of family members. About 56% believe PCTs carries a risk of burdensome interventions and 52% increased hospital stay at EOL while 47% are of the opinion it will increase cost of care with 45% stating it will lead to increased ICU death. Sixty-nine percent (69%) and 63% respectively agree PCTs increases the suffering of patients and family members while 43% believe it carries a net negative risk-benefit profile, nevertheless, 83% are ready to overlook the risk of PCTs for possible therapeutic benefit while for 87%, the primary motivation for PCTs is personal cure. Majority (58%) believe PCTs does not improve quality of dying/death contrary to PEOLC where 88% believe it would improve the quality of dying/death. Overall, by direct comparison 78%:13% prefer PEOL to PCTs; {X2(p-value), 40.26(0.001)}. Conclusions: Both modalities are acceptable to advanced cancer patients but the study reveals several ethical issues with PCTs including risk of burdensome interventions, suffering of patients, therapeutic misconception and misperception of curability. A major determinant to accepting PEOL is its positive impact on patients’ QOL. Concerted efforts are needed to significantly enhance access of PEOLC to cancer patients.

scholarly journals Transfusion practices at end of life for hematopoietic stem cell transplant patients

2017 ◽  
Vol 26 (6) ◽  
pp. 1927-1931 ◽  
Author(s):  
Winnie S. Wang ◽  
Joseph D. Ma ◽  
Sandahl H. Nelson ◽  
Carolyn Revta ◽  
Gary T. Buckholz ◽  
...  
Keyword(s):  
Stem Cell ◽  
End Of Life ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Transplant Patients
Sign in / Sign up

Export Citation Format

Share Document